DUBLIN–(BUSINESS WIRE)–The “CAR-T Cell Therapy Market by Target Indications, Target Antigens, Key Players and Key Geographies – Global Forecast 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
Cancer is the one of the leading cause of deaths, globally. In fact, as per the World Health Organization (WHO), 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities as well as the national health systems.
Even though a number of treatment options are available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is still difficult to achieve. Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T cell therapy, a relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR-T cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.
At present, more than 5 CAR-T therapies have been approved for several hematological malignancies, including KYMRIAH (Novartis), YESCARTA (Gilead Sciences), TECARTUST (Gilead Sciences), Breyanzi (Bristol Myers Squibb), AbecmaT (Bristol Myers Squibb) and CARVYKTIT (Janssen Biotech / Legend Biotech). In fact, more than 170 companies are engaged in the development of over 970 early and late-stage CAR-T therapies, worldwide.
Moreover, several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,500 patents related to CAR-T cell therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, more than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates.
To fund product development initiatives, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR-T cell therapy market is likely to witness significant growth in the foreseen future.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. CAR-T CELL THERAPIES: MARKET LANDSCAPE
5. KEY INSIGHTS
6. CLINICAL TRIAL ANALYSIS
7. KEY OPINION LEADERS
8. CAR-T CELL THERAPY PROFILES
9. PARTNERSHIPS AND COLLABORATIONS
10. FUNDING AND INVESTMENT ANALYSIS
11. PATENT ANALYSIS
12. CASE STUDY: CELL THERAPY MANUFACTURING
13. COST PRICE ANALYSIS
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15. PROMOTIONAL ANALYSIS
16. COMPANY PROFILES
17. CONCLUDING REMARKS
18 EXECUTIVE INSIGHTS
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
920th Hospital of Joint Logistics Support Force
AbbVie Ventures
AbCellera
AbCheck
AbClon
Abound Bio
Abzena
Acibadem University
ACROBiosystems
AdAlta
Adaptimmune Therapeutics
Adicet Bio
Adimab
Affiliated Hospital of Jiangnan University
Affiliated Hospital of Jiangsu University
Affiliated Hospital to Academy of Military Medical Sciences
Affiliated Zhongshan Hospital of Dalian University
AffyImmune Therapeutics
AGC Biologics
Agreen Biotech
AK (Suzhou) Biomedical
Alaunos Therapeutics
Aleta Biotherapeutics
Alexandria Venture Investments
Allife Medical Science and Technology
Allogene Therapeutics
Alpha Biopharma
Amgen Ventures
Beth Israel Deaconess Medical Center (BIDMC)
Bioceltech Therapeutics
Bio-Gene Technology
BioLife Solutions
Bionomics
BioNTech
Bioray Laboratories
Biosceptre
Bluebird Bio
Boya Jiyin
BoYuan RunSheng Pharma (Hangzhou)
Bristol-Myers Squibb
Cabaletta Bio
Cabaret Biotech
Calibr
California Institute for Regenerative Medicine (CIRM)
Cellex Patient Treatment
CELLforCURE
CellPoint
Cellular Biomedicine Group
Cellvec
Celularity
Celyad Oncology
Center for International Blood and Marrow Transplant Research
Central South University
Changhai Hospital
Chengdu USino Technology Biology
Chongqing University Cancer Hospital
City of Hope Medical Center
Eureka Therapeutics
Eutilex
EXUMA Biotech
Fate Therapeutics
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Fidelity Management & Research
First People’s Hospital of Foshan
Five Prime Therapeutics
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Fondo Social La Caixa
Formula Pharmaceuticals
Fosun Pharmaceutical
Fourth Hospital of Hebei Medical University
Fraunhofer
Fred Hutchinson Cancer Research
Fred Hutchinson Cancer Research Center
Fudan University
Fujian Medical University
Fundamenta Therapeutics
FutureGen Biopharm
G Plus Life Sciences
GE Global Research
GE Healthcare
Guangzhou 8th People’s Hospital
Guangzhou Anjie Biomedical Technology
Guangzhou First People’s Hospital
Hunan Yongren Medical Innovation
Hunan Zhaotai Yongren Biotech
Hunan Zhaotai Yongren Medical Innovation
IASO Biotherapeutics
iCAR Bio Therapeutics
iCarTAB BioMed
iCell Gene Therapeutics
ICON
And More
For more information about this report visit https://www.researchandmarkets.com/r/tyfeus
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
